GlassScriptPhysician profile
Amanda Gonnella
NPI 1740959279
$459.95
in general payments reported to CMS, 2019-2025
12 companies · $236 in 2025
The $236 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $41.96 · 2024: $182 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $126.91 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Ibsa Pharma INC. | $62.15 | 2023-2025 | Tirosint, Licart, Flector |
| Merck Sharp & Dohme LLC | $59.98 | 2024 | Vaxelis, Vaxneuvance, Gardasil |
| Astrazeneca Pharmaceuticals LP | $31.22 | 2024 | Breztri |
| Alk-Abello, INC | $28.17 | 2025 | Neffy, Grastek, Odactra |
| Lilly USA, LLC | $24.46 | 2025 | Zepbound, Mounjaro |
| Sumitomo Pharma America, INC. | $24.03 | 2025 | Gemtesa |
| Abbvie INC. | $22.26 | 2025 | |
| Antares Pharma, INC. | $21.93 | 2023 | Xyosted, Tlando, Nocdurna |
| Abbott Laboratories | $21.71 | 2025 | Freestyle Libre 3 |
| Vertex Pharmaceuticals Incorporated | $21.08 | 2025 | |
| Pfizer INC. | $16.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Gonnella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.